A cohort study including 246 patients with active disease and depression within 30 days prior to the initiation of anti-TNF treatment showed that increased baseline depressive symptoms assessment score was significantly associated with a higher probability of non-compliance with anti-TNF therapy over 2 years of follow-up (HR: 2.28; 95% CI: 1.1–4.6) [130]. The gene discussed is TNF; the disease is depressive symptom measurement.